Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 153 participants.

Also called NCT03140631

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 153 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03140631
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03140631. Randomized; no masking; primary purpose treatment. Start 2017-03-23 (actual); primary completion 2017-11-16 (actual). Results posted on 2018-10-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation
Intervention (Drug)
Protamine Sulfate
Lead sponsor
University of Michigan (class: other)

Record details

Record id
cardio:ct-nct03140631
Content hash
c562626d186c1886369489cd90ae9ed56f676f038ca83b551e335d143e4f70fa